APH1A as a Radioligand Therapy Target
APH1A, aph-1A gamma-secretase subunit, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, APH1A staining is highest in thyroid cancer (100% of samples positive), neuroendocrine tumors (100% of samples positive) and melanoma (100% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is APH1A a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
APH1A expression in cancer
Protein expression of APH1A across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 1.00 | High | 100% |
| Neuroendocrine Tumors | 1.00 | High | 100% |
| Melanoma | 0.97 | High | 100% |
| Kidney Cancer | 0.97 | High | 100% |
| Lung Cancer | 0.97 | High | 100% |
| Endometrial Cancer | 0.97 | High | 100% |
| Liver Cancer | 0.97 | High | 100% |
| Breast Cancer | 0.97 | High | 100% |
| Lymphoma | 0.94 | High | 100% |
| Colorectal Cancer | 0.92 | High | 100% |
| Ovarian Cancer | 0.92 | High | 100% |
| Head and Neck Cancer | 0.89 | High | 100% |
| Cervical Cancer | 0.89 | High | 100% |
| Pancreatic Cancer | 0.89 | High | 89% |
| Bladder Cancer | 0.88 | High | 100% |
| Prostate Cancer | 0.88 | High | 100% |
| Gastric Cancer | 0.87 | High | 100% |
| Skin Cancer | 0.81 | High | 100% |
| Glioma | 0.80 | High | 100% |
| Testicular Cancer | 0.72 | High | 100% |
Is APH1A internalized?
Nuclens has not yet extracted internalization evidence for APH1A. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
APH1A clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for APH1A yet. Search ClinicalTrials.gov for APH1A trials.
APH1A normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See APH1A in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
APH1A gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.18 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how APH1A ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.